Sharechat Logo

ASX-listed Volpara Health in trading halt pending capital raising

Thursday 26th April 2018

Text too small?

ASX-listed Volpara Health Technologies is in a trading halt while the Kiwi digital health firm raises capital from institutional investors ahead of next week's quarterly cash flow report. 


Wellington-based Volpara, which focuses on early detection of breast cancer using artificial intelligence, sought a trading halt on the ASX today to let company raise money through an institutional placement "in an orderly manner", it said in a statement. The placement is part of a proposed capital raising, which will also include a share purchase plan for existing investors. 


The shares last traded at 69 Australian cents, and while they've dipped 1.4 percent so far this year, the stock is still trading above its 2016 initial public offering price of 50 cents. 


The halt will lift once Volpara announces the outcome of the placement or when trading opens on Monday. 


The company this month said it beat its goal of lifting annual recurring revenue 200 percent in the March 2018 year, with ARR at $3.6 million as at March 31. Volpara is scheduled to release its quarterly cash flow statement and hold an investor briefing on April 30. It had cash on hand of $7 million as at Dec. 31. 



  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

ASB reviews ownership of Aegis
Auckland Airport kicks off next phase of expansion
Cashed-up Plexure eyes acquisitions to accelerate growth as loss shrinks
Tower turns to 1H profit, lifts FY guidance
IRD should have doubled claim against Watson's Cullen Group - Professor
Investore FY profit falls 16% on smaller valuation gain, signals flat dividend for 2020
Synlait receives cease and desist letter regarding Pokeno plant
21st May 2019 Morning Report
NZ dollar steady ahead of central bank speeches
Auditors need to come out of the shadows and explain the value they add: FMA

IRG See IRG research reports